Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 17015476
Leung-Pineda V, Ryan CE, Piwnica-Worms H (2006) Phosphorylation of Chk1 by ATR is antagonized by a Chk1-regulated protein phosphatase 2A circuit. Mol Cell Biol 26, 7529-38 17015476
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S1981-p - ATM (human)
Modsite: sLAFEEGsQSTtIss SwissProt Entrez-Gene
Orthologous residues
ATM (human): S1981‑p, ATM (mouse): S1987‑p, ATM (rat): S1988‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  ataxia-telangiectasia
Relevant cell lines - cell types - tissues:  AT22IJE-T (fibroblast), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Go_6976 no change compared to control
hydroxyurea increase
etoposide increase

S1423-p - BRCA1 (human)
Modsite: AVLEQHGsQPSNSYP SwissProt Entrez-Gene
Orthologous residues
BRCA1 (human): S1423‑p, BRCA1 iso6 (human): S320‑p, BRCA1 iso7 (human): S1423‑p, BRCA1 (mouse): N1379‑p, BRCA1 (rat): S1380‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  ataxia-telangiectasia
Relevant cell lines - cell types - tissues:  AT22IJE-T (fibroblast), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
etoposide increase
Go_6976 no change compared to control
hydroxyurea no change compared to control
UCN-01 no change compared to control

S317-p - Chk1 (human)
Modsite: ENVkYsssQPEPRTG SwissProt Entrez-Gene
Orthologous residues
Chk1 (human): S317‑p, Chk1 (mouse): S317‑p, Chk1 (rat): S317‑p, Chk1 (chicken): S317‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  ataxia-telangiectasia
Relevant cell lines - cell types - tissues:  AT22IJE-T (fibroblast), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
PHOSPHATASE PPP2CA (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE PPP2CA (human) pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme, phospho-antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Go_6976 increase
siRNA Go_6976 PPP1CA (human) inhibit treatment-induced increase
siRNA Go_6976 PPP2CA (human) augment treatment-induced increase
hydroxyurea increase
okadaic_acid increase
fostriecin increase
siRNA PPP1CA (human) no change compared to control
siRNA PPP2CA (human) increase

S345-p - Chk1 (human)
Modsite: LVQGIsFsQPtCPDH SwissProt Entrez-Gene
Orthologous residues
Chk1 (human): S345‑p, Chk1 (mouse): S345‑p, Chk1 (rat): S345‑p, Chk1 (chicken): S345‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  ataxia-telangiectasia
Relevant cell lines - cell types - tissues:  AT22IJE-T (fibroblast), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
PHOSPHATASE PPP2CA (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE PPP2CA (human) pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme, phospho-antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Go_6976 increase
wortmannin Go_6976 inhibit treatment-induced increase
siRNA Go_6976 ATR (human) inhibit treatment-induced increase
Go_6976 ATM (human) no effect upon treatment-induced increase ATM deficient cells
siRNA Go_6976 PPP1CA (human) inhibit treatment-induced increase
siRNA Go_6976 PPP2CA (human) augment treatment-induced increase
SB218078 increase
UCN-01 increase
hydroxyurea increase
etoposide increase
okadaic_acid increase
siRNA PPP1CA (human) no change compared to control
siRNA PPP2CA (human) increase

S139-p - H2AX (human)
Modsite: GkkAtQAsQEy____ SwissProt Entrez-Gene
Orthologous residues
H2AX (human): S139‑p, H2AX (mouse): S139‑p, H2AX (rat): S139‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  ataxia-telangiectasia
Relevant cell lines - cell types - tissues:  AT22IJE-T (fibroblast), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Go_6976 no change compared to control
hydroxyurea increase
etoposide increase

S966-p - Smc1 (human)
Modsite: GEDsVsGsQRIssIy SwissProt Entrez-Gene
Orthologous residues
Smc1 (human): S966‑p, Smc1 (mouse): S966‑p, Smc1 (rat): S966‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  ataxia-telangiectasia
Relevant cell lines - cell types - tissues:  AT22IJE-T (fibroblast), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Go_6976 no change compared to control
hydroxyurea increase
etoposide increase